ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Small molecule inhibitors such as BV02 have also been identified, which disrupt the 14-3-3/c-Abl interaction, leading to the release of c-Abl and its pro-apoptotic functions, suggesting potential therapeutic applications in chronic myeloid leukemia.110,111